Alterity Therapeutics Ltd. has announced positive topline data from its open-label Phase 2 clinical trial of ATH434 in individuals with multiple system atrophy $(MSA)$. The ATH434-202 trial assessed a patient population with more advanced MSA compared to the cohort in the earlier double-blind Phase 2 trial, ATH434-201. The results demonstrated clinical benefits on the Unified MSA Rating Scale and global measures of neurological symptoms, with neuroimaging biomarkers indicating target engagement and slowed brain atrophy. ATH434 was well-tolerated and exhibited a favorable safety profile. These findings align with previous data from the Phase 2 double-blind trial and support the further advancement of ATH434 in the treatment of MSA. As of now, there are no disease-modifying medications available for MSA, making the development of ATH434 significant. The results have been presented and are consistent with Alterity's ongoing efforts to address neurodegenerative diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.